RDUS 27.810+103.59% 天美生物 BON 1.4400+95.73% USA Rare Earth USAR 18.550+72.00% SUNation Energy SUNE 0.525+64.11% D-Wave Quantum QBTS 10.150+46.89% 查看每日涨幅最大股票 分析 分析师评级 更新时间: 2025/02/28 买入 买入 100.00% 持有 ...
Mesoblast stock price target cut to $7 from $12 at Dawson James Jul. 19, 2022 at 10:05 a.m. ET by Tomi Kilgore Mesoblast upgraded to buy from hold at Maxim Group Apr. 7, 2021 at 7:36 a.m. ET by Tomi Kilgore Mesoblast stock price target cut to $16 from $20 at Dawso...
美股市场个股详情 MESO Mesoblast 添加自选 13.550 +0.270+2.03% 收盘价 03/14 16:00 (美东) 13.290 -0.260-1.92% 盘前08:41 (美东) 17.21亿总市值-14.43市盈率TTM 13.575最高价13.140最低价32.94万股成交量13.260今开13.280昨收440.85万成交额0.46%换手率亏损市盈率(静)1.27亿总股本22.00052周最高3.73市净率...
NASDAQ:MESO实时 13.940.261.90%2025-03-21 16:00:00 今开:13.75 昨收:13.68 今日区间:13.60-14.06 52周区间:1.61-12.18 成交量:27.06万 成交额:376.48万 市值:17.84亿 市盈率:0.00 贝塔系数: 每股收益:-0.8893 盘后14.510.574.09%成交量0.02万2025-03-21 20:00...
Historical and current end-of-day data provided by FACTSET. All quotes are in local exchange time. Real-time last sale data for U.S. stock quotes reflect trades reported through Nasdaq only. Intraday data delayed at least 15 minutes or per exchange requirements. ...
A high-level overview of Mesoblast Limited (MESO) stock. View (MESO) real-time stock price, chart, news, analysis, analyst reviews and more.
Strike PriceChange% ChangeBidAskVolumeOpen IntLast Trade Time 14.00 4.70 -2.80 -37.33% 3.00 5.10 1 33 1:22 PM 01/24/25 15.00 2.45 -3.60 -59.50% 1.65 4.10 1 18 10:38 AM 01/17/25 16.00 1.92 -0.03 -1.54% 0.00 3.30 1 2 10:39 AM 01/17/25 ...
Is MESO Stock a Buy, Sell, or Hold? Turning to Wall Street, the analysts’ consensus rating for Mesoblast is Strong Buy based on two Buy ratings over the last three months. With that comes an average price target of $22.50, a high of $30, and a low of $15. This represents a pot...
Market Cap 1.14B Stock Price 17.15 Revenue $0000 About Mesoblast Mesoblast specializes in the development and commercialization of innovative allogeneic cellular medicines for the treatment of serious and life-threatening inflammatory diseases within the biotechnology sector. The company's main offerings in...
Mesoblast(MESO.US)宣布其抗炎细胞疗法remestemcel-L三期临床试验结果不及预期智通财经APP获悉,上周五,Mesoblast(MESO.US)称,其remestemcel-L治疗在用于卫生事件引发的ARDS(急性呼吸窘迫综合征)的三期临床试验中,未能达到30天死亡率降低的目标。该试验包括300名患者,目标是在30天内死亡率降低43%,在给予最大限度护理的...